Paratek Pharmaceuticals, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation, amortization and accretion
Stock-based compensation expense
Noncash interest expense
Impairment of intangible assets
Employee stock purchase plans
Changes in fair value of contingent consideration
Loss on extinguishment of debt
Changes in operating assets and liabilities
Accounts receivable, prepaid, and other current assets
Purchase of prepaid interest - marketable securities
Accounts receivable, other receivables, prepaid, and other current assets
Inventories
Operating lease right-of-use asset
Accounts payable and accrued expenses
Long-term operating lease liability
Operating lease liability
Accrued long-term compensation
Other liabilities and other assets

Net cash used in operating activities
Investing activities
Purchase of fixed assets
Purchase of marketable securities
Proceeds from maturities of marketable securities
Net cash provided by investing activities
Financing activities
Proceeds from issuance of long-term convertible debt, net of costs
Proceeds from issuance of long-term debt, net of costs
Convertible Debt
Royalty Backed Loan Agreement
Total proceeds from issuance of long-term debt, net of costs

Payment of long-term royalty-backed loan agreement debt issuance costs
Proceeds from employee stock purchase plan
Proceeds from exercise of stock options
Principal payments on long-term debt
Proceeds from issuance of common stock, net
Net cash provided by financing activities

Net increase (decrease) in cash, cash equivalents and restricted cash
Net decrease in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at the beginning of period
Cash, cash equivalents and restricted cash at end of period
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for interest
Debt issuance costs in accrued expenses
Purchases of equipment included in accrued expenses
SUPPLEMENTAL DISCLOSURES OF NONCASH FINANCING ACTIVITIES
Paid in-kind interest included in accrued expenses
Fair value of warrants issued

Comments